Twenty years on, survivors of testicular cancer still have large amounts of
platinum circulating in their blood, from their chemotherapy. A team from the
University of Groningen in the Netherlands examined 61 men who had been treated
with the platinum-containing drug cisplatin. Between 10 and 20 years later the
men had an average of 65 picograms per gram of plasma. Among 20 controls, who
survived testicular cancer without chemotherapy, 18 had no platinum and two had
only traces (The Lancet, vol 355, p 1075). The team says the drug’s
persistence justifies research into long-term side effects.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features

Advertorial
The defence sector can’t adopt a ‘one-size-fits-all’ approach to AI
Advertising

Advertorial
Why the future of defence is drone tech and distributed edge computing
Advertising

Advertorial
The future of defence lies in transatlantic industrial partnerships
Advertising

Advertorial
The biggest defence risk is a lack of integration, not technology
Advertising
Popular articles
Trending New Scientist articles
1
A quantum state that lasts forever may finally be within our grasp
2
We've found a mysterious substance on Titan and Pluto
3
Faecal transplant makes the brains of old mice act young again
4
The secrets to keeping your brain sharp in old age
5
Has the answer to life's origins been hiding in our cells all along?
6
Remarkable fossils rewrite the story of how animals conquered the land
7
Autism may have two distinct subtypes that vary by brain activity
8
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
9
How to sparkle in conversation with strangers
10
How I used psychology to come back from the worst year of my life